MiNK Therapeutics, Inc. (INKT)
INKTNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$10.01
0.0000 (0.00%) today
Pre-market, Nov 10, 4:00 PM ET
- Market cap
- $51.08m
- P/E
- –
- EPS, last 4 quarters
- $-2.40
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.48 to $16.93
- Average volume
- 15.7k
- Previous close
- $10.01
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $44.00, +339.6% from here
Earnings
next estimate $-0.6600Next report
Sep 2025
+24.4%
Dec 2025
+17.6%
Mar 2026
+26.0%
Jun 2026
-3.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.18m | -$2.71m | -$2.88m | -$3.22m |
| Net income | -$2.89m | -$2.60m | -$2.74m | -$3.13m |
News
8 latest- MiNK Selected For ARPA-H Program To Advance Room-Temperature Cell Therapy RTTNews · Sep 30, 2026
- MiNK Therapeutics (INKT) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
- MiNK Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
- Here's Why You Should Add INKT Stock to Your Portfolio NowZacks · Jul 16, 2026
- Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest RTTNews · May 29, 2026
- MiNK (INKT) Q4 2025 Earnings Call TranscriptThe Motley Fool · May 15, 2026
- MiNK (INKT) Q1 2026 Earnings Call TranscriptThe Motley Fool · May 15, 2026
- MiNK Therapeutics Q1 Earnings Call HighlightsMarketBeat · May 15, 2026
The company
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK's proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse. Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK's pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- minktherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.